BSX

Boston Scientific's stock price has experienced a significant decline over the past year, decreasing by 56.01% from October 7, 2025, to October 6, 2026, and reaching a new 52-week low of $41.50 in October 2026. Key events impacting the stock price in the past six months include the company lowering its full-year 2026 guidance for both adjusted EPS and sales following its Q2 2026 earnings report, attributing this to unanticipated headwinds in its Electrophysiology, WATCHMAN, and Urology segments. In August and September 2026, a cyberattack disrupted global operations for a couple of weeks, estimated to impact third-quarter results by approximately $300 million in sales and $0.13 per share in earnings. On October 7, 2026, Boston Scientific announced the appointment of Joseph M. Fitzgerald as Executive Vice President and Chief Operating Officer, effective January 1, 2027, alongside a new organizational structure dividing operations into three distinct segments: Interventional Therapies, Rhythm Solutions, and MedSurg. Additionally, in May 2026, the company announced a strategic investment in MiRus LLC and entered into a $2 billion accelerated share repurchase agreement, and in January 2026, it announced an agreement to acquire Penumbra, Inc.